Press coverage about Citius Pharmaceuticals (NASDAQ:CTXR) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Citius Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.02053539045 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Citius Pharmaceuticals (CTXR) opened at $4.77 on Tuesday. Citius Pharmaceuticals has a 52 week low of $2.55 and a 52 week high of $14.85.

In related news, insider Leonard L. Mazur acquired 11,000 shares of Citius Pharmaceuticals stock in a transaction on Thursday, August 24th. The stock was acquired at an average price of $2.68 per share, for a total transaction of $29,480.00. Following the purchase, the insider now owns 3,337,730 shares of the company’s stock, valued at approximately $8,945,116.40. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

ILLEGAL ACTIVITY WARNING: This report was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-citius-pharmaceuticals-ctxr-stock-price/1716974.html.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream.

Insider Buying and Selling by Quarter for Citius Pharmaceuticals (NASDAQ:CTXR)

Receive News & Ratings for Citius Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.